and it's LLY! anyone have any thoughts on whether Bristol will sweeten its offer? i think anything over 70/share is too much. even at 70, they might be paying too much already.
also, do you guys like imclone's pipeline. sure, erbitux is no stellar drug, but it's revenue stream is still decent.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.